智通财经网·2025-10-26 11:08Core Viewpoint - WuXi AppTec (02359) announced a sale agreement where its wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., will sell its shares in Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Hillhouse Capital for cash consideration, reflecting the company's strategic focus on its core CRDMO business model [1] Group 1 - The transaction is expected to provide financial support to accelerate global capabilities and capacity development, enhancing service to clients and benefiting global patients [1] - Hillhouse Capital is recognized as a leading global private asset management firm, focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology [1] Group 2 - From January to September 2025, Kande Hongyi and Jinshi Pharmaceutical generated a total revenue of RMB 1.16 billion (unaudited), accounting for approximately 3.5% of the company's unaudited revenue for the first three quarters of 2025 [1] - During the same period, the net profit from Kande Hongyi and Jinshi Pharmaceutical amounted to RMB 90 million (unaudited), representing about 0.7% of the company's unaudited net profit for the first three quarters of 2025 [1]